Analysis of ERBB2 and TOP2A gene status using fluorescence in situ hybridization versus immunohistochemistry in localized breast cancer

Neoplasma

Volumn 53, Issue 5, 2006, Pages 393-401

  Bouchalova K ^a   Trojanec, R ^a   Kolar Z ^a   Cwiertka, K ^a   Cernakova I ^a   Mihal V ^a   Hajduch M ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Anthracycline; Breast carcinoma; ERBB2; FISH; Immunohistochemistry; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); DNA TOPOISOMERASE INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY; TOPOISOMERASE 2ALPHA; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER LOCALIZATION; CANCER STAGING; CHROMOSOME 17; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE LOCUS; GENE NUMBER; GENETIC ANALYSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; SIGNAL TRANSDUCTION;

EID: 33750611131     PISSN: 00282685     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. JARVINEN TA, TANNER M, BARLUND M, BORG A, ISOLA J. Characterization of topoisomerase II alpha gene amplification and deletion in breast cancer. Genes Chromosomes Cancer 1999; 26: 142-150.
2. SLAMON DJ, CLARK GM, WONG SG. LEVIN WJ, ULLRICH A et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182.
3. VOGEL CL, COBLEIGH MA, TRIPATHY D, GUTHEIL JC, HARRIS LN et al. First-line Herceptin monotherapy in metastatic breast cancer. Oncology 2001; 61 Suppl 2: 37-42.
4. ALTON PA, HARRIS AL. The role of DNA topoisomerases II in drug resistance. Br J Haematol 1993; 85: 241-245.
5. DANDACHI N, DIETZE O, HAUSER-KRONBERGER C. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer. Anticancer Res 2004; 24: 2401-2406.
6. JACOBS TW, GOWN AM, YAZIJI H, BARNES MJ, SCHNITT SJ. Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer. J Clin Oncol 1999; 17: 1974-1782.
7. JACOBS TW, GOWN AM, YAZIJI H, BARNES MJ, SCHNITT SJ. Specificity of HercepTest in determining HER-2/neu status of breast cancers using the United States Food and Drug Administration-approved scoring system. J Clin Oncol 1999; 17: 1983-1987.
8. RAVDIN PM. Should HER2 status be routinely measured for all breast cancer patients? Semin Oncol 1999; 26: 117-123.
9. ROSS JS, FLETCHER JA. The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 1998; 16: 413-428.
10. ROSS JS, FLETCHER JA. The HER-2/neu oncogene: prognostic factor, predictive factor and target for therapy. Semin Cancer Biol 1999; 9: 125-138.
11. VERA-ROMAN JM, RUBIO-MARTINEZ LA. Comparative assays for the HER-2/neu oncogene status in breast cancer. Arch Pathol Lab Med 2004; 128: 627-633.
12. WANG S, SABOORIAN MH, FRENKEL E, HYNAN L, GOKASLAN ST et al. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000; 53: 374-381.
13. ELLIS IO, DOWSETT M, BARTLETT J, WALKER R, COOKE T et al. Recommendations for HER2 testing in the UK. J Clin Pathol 2000; 53: 890-892.
14. SLAMON DJ, LEYLAND-JONES B, SHAK S, FUCHS H, PATON V et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.
15. EISENHAUER EA. From the molecule to the clinic-inhibiting HER2 to treat breast cancer. N Engl J Med 2001; 344: 841-842.
16. PEREZ EA, ROCHE PC, JENKINS RB, REYNOLDS CA, HALLING KC et al. HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc 2002; 77: 148-154.
17. MASS RD, PRESS MF, ANDERSON S, COBLEIGH MA, VOGEL CL et al. Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab. Clin Breast Cancer 2005; 6: 240-246.
18. MUELLER RE, PARKES RK, ANDRULIS I, O'MALLEY FP. Amplification of the TOP2 A gene does not predict high levels of topoisomerase II alpha protein in human breast tumor samples. Genes Chromosomes Cancer 2004; 39: 288-297.
19. HEDLEY DW, FRIEDLANDER ML, TAYLOR IW, RUGG CA, MUSGROVE EA. Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 1983; 31: 1333-1335.
20. HOPMAN AH, VAN HOOREN E, VAN DE KAA CA, VOOIJS PG, RAMAEKERS FC. Detection of numerical chromosome aberrations using in situ hybridization in paraffin sections of routinely processed bladder cancers. Mod Pathol 1991; 4: 503-513.
21. MARK HF, FELDMAN D, DAS S, KYE H, MARK S et al. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer. Exp Mol Pathol 1999; 66: 170-178.
22. MARK HF, TAYLOR W, AFIFY A, RIERA D, RAUSCH M et al. Stage I and stage II infiltrating ductal carcinoma of the breast analyzed for chromosome 8 copy number using fluorescent in situ hybridization. Pathobiology 1997; 65: 184-189.
23. MARK HF. Fluorescent in situ hybridization as an adjunct to conventional cytogenetics. Ann Clin Lab Sci 1994; 24: 153-163.
24. PINKEL D, STRAUME T, GRAY JW. Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization. Proc Natl Acad Sci 1986; 83: 2934-2938.
25. TUBES RR, PETTAY JD, ROCHE PC, STOLER MH, JENKINS RB et al. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001; 19: 2714-2721.
26. [261 KOLAR Z, MURRAY PG, SCOTT K, HARRISON A. VOJTESEK B et al. Relation of Bcl-2 expression to androgen receptor, p21WAF1/CIP1, and cyclin D1 status in prostate cancer. Mol Pathol 2000; 53: 15-18.
27. THOMPSON FH. Cytogenetic methods and findings in human solid tumors. In: Barch MJ, Knutsen T, Spurbeck JL, editors. The AGT Cytogenetics Laboratory Manual. Philadelphia: Lippincott-Raven, 1997: 407-408.
28. MCKAY JA, MURRAY GI, KEITH WN, MCLEOD HL. Amplification of fluorescent in situ hybridisation signals in formalin fixed paraffin wax embedded sections of colon tumour using biotinylated tyramide. Mol Pathol 1997; 50: 322-325.
29. LEBEAU A, DEIMLING D, KALTZ C, SENDELHOFERT A, IFF A et al. Her-2/neu analysis in archival tissue samples of human breast cancer: comparison of immunohistochemistry and fluorescence in situ hybridization. J Clin Oncol 2001; 19: 354-363.
30. ROCHE PC, SUMAN VJ, JENKINS RB, DAVIDSON NE, MARTINO S et al. Concordance between local and central laboratory HER2 testing in the breast intergroup trial N9831. J Natl Cancer Inst 2002; 94: 855-857.
31. NELSON WG, CHO KR, HSIANG YH, LIU LF, COFFEY DS. Growth-related elevations of DNA topoisomerase II levels found in Dunning R3327 rat prostatic adenocarcinomas. Cancer Res 1987; 47: 3246-3250.
32. HECK MM, EARNSHAW WC. Topoisomerase II: A specific marker for cell proliferation. J Cell Biol 1986; 103: 2569-2581.
33. HECK MM, HITTELMAN WN, EARNSHAW WC. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc Natl Acad Sci 1988; 85: 1086-1090.
34. HSIANG YH, WU HY, LIU LF. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res 1988; 48: 3230-3235.
35. SMITH K, HOULBROOK S, GREENALL M, CARMICHAEL J, HARRIS AL. Topoisomerase II alpha co-amplification with erbB2 in human primary breast cancer and breast cancer cell lines: relationship to m-AMSA and mitoxantrone sensitivity. Oncogene 1993; 8: 933-938.
36. JARVINEN TA, LIU ET. HER-2/neu and topoisomerase IIalpha in breast cancer. Breast Cancer Res Treat 2003; 78: 299-311.
37. DURBECQ V, DI LEO A, CARDOSO F, ROUAS G, LEROY JY et al. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. Breast Cancer Res Treat 2003; 77: 199-204.
38. HICKS DG, YODER BJ, PETTAY J, SWAIN E, TARR S et al. The incidence of topoisomerase II-alpha genomic alterations in adenocarcinoma of the breast and their relationship to human epidermal growth factor receptor-2 gene amplification: a fluorescence in situ hybridization study. Hum Pathol 2005; 36: 348-356.
39. JARVINEN TA, TANNER M, RANTANEN V, BARLUND M, BORG A et al. Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer. Am J Pathol 2000; 156: 839-847.
40. BOFIN AM, YTTERHUS B, HAGMAR BM. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 2003; 14: 314-319.
41. KNOOP AS, KNUDSEN H, BALSLEV E, RASMUSSEN BB, OVERGAARD J et al. Retrospective analysis of topoisomerase IIalpha amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol 2005; 23: 7483-7490.
42. OLSEN KE, KNUDSEN H, RASMUSSEN BB, BALSLEV E, KNOOP A et al. Amplification of HER2 and TOP2A and deletion of TOP2A genes in breast cancer investigated by new FISH probes. Acta Oncol 2004; 43: 35-42.